Can you tell which one of these patients is at high risk for acute rejection after their kidney transplant?
Tutivia™ is a blood-based proactive risk assessment tool for acute rejection in
your kidney transplant patients. Tutivia™ uses RNA sequencing technology that
helps answer your questions to deliver a more patient-centric care plan.
Which of my patients is at high risk for acute rejection?
How do I know if a patient has Acute Rejection (AR) or BK Nephropathy (BKN)?
How do I manage patients with Delayed Graft Function (DGF)?
Why Tutivia™?
When a patient receives a high-risk Tutivia™ result, the hazard ratio of that patient having AR is 5.74 over a low-risk result.
The high hazard ratio increases confidence in making informed treatment decisions.
1 Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection. Am J Transplant. 2020;20:2318–2331. https://doi.org/10.1111/ajt.15898
HIGH SENSITIVITY IN INDICATION BIOPSIES EVEN WITHIN 60 DAYS POST TRANSPLANT
RNA signatures offer precision as early as first week post-transplant as they are not markers of injury that may be confounded by the initial surgery.
Offering an early ability to risk stratify your patients offers you an opportunity to manage your patients proactively.
BKN
BK can be difficult to differentiate from rejection.
In the clinical validation study, the BKN patients returned a low risk for AR result.
This differentiation may be important in your clinical decision making.
DGF
DGF presents clinically challenging complications post transplant.
Click here to learn the role of Tutivia™ in patients where DGF may be suspected.
How was Tutivia™ Studied?
Tutivia™ was studied as a prospective, multicenter (13 contributing transplant sites), blinded, international trial that allowed for the inclusion of diverse populations and broad diversity in care management practices; while allowing blinding to protect from the introduction of biases; thereby producing robust and reliable results for clinical integration.
The complexity of issues facing clinicians in their clinics was reflected as much as was possible in the study design.
All evaluable participants (n = 151) enrolled at 13 contributing centers in 5 countries were included in the Tutivia™ validation. Each study participant had blood collected at the time of for-cause (n = 44) or protocol biopsy (n = 107) within the first 6 months following transplant. Each biopsy was read centrally by an expert in renal pathology to identify and characterize rejection phenotypes. In 151 unique patients, 46 (30%) rejection events were characterized according to current (2019) BANFF criteria, including borderline TCMR3. Mean time to rejection was 61.1 days; range: 6 - 175d. Additionally, BK Nephropathy was identified in 6 patients and pyelonephritis in 3 patients.
To expand on the statement above, early evidence shows Tutivia™ has the ability to differentiate between BK nephropathy and acute rejection. In our validation study, 6 cases of BK virus were identified without raising risk score for rejection. Illustrating a promising impact on treating patients where BK is suspected.
Early evidence also illustrates Tutivia™ was able to identify acute rejection as early as 6 days. In addition, Tutivia™ had an 83% sensitivity (20/24) in identifying rejection when a for cause biopsy was done <60 days post-transplant. This early indicator helps establish a reference point for future testing.
Tutivia™ risk scores are calculated continuously from 0-100; for interpretation, a pre-determined risk cut-point of 50 was established based on the independent training set. The risk score distribution (fig. 1) resulted in 26.5% of patients with a high risk (>50) score result in which 60% were shown to correlate with rejection on histopathology; low risk score results in 73.5% of patients correlated with an absence of rejection on histopathology findings in 79% of patients. The receiver operating characteristic curve AUC was 0.693, P<0.001.
Tutivia™ is a blood-based transcriptomic RNA expression signature that utilizes a proprietary
AI algorithm to assign a risk score for acute rejection with correlation to kidney biopsy, across
the entire BANFF 2019 histological continuum. Tutivia™ is able to assist the clinician in actionable
decisions, regarding treatment of kidney transplant patients at risk for acute rejection.
We use cookies to optimize our website and our service.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
We use cookies to optimize our website and our service.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Which of my patients is at high risk for acute rejection?
